171 related articles for article (PubMed ID: 36508458)
1. Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Stolk WA; Coffeng LE; Bolay FK; Eneanya OA; Fischer PU; Hollingsworth TD; Koudou BG; Méité A; Michael E; Prada JM; Caja Rivera RM; Sharma S; Touloupou P; Weil GJ; de Vlas SJ
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010953. PubMed ID: 36508458
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
[TBL] [Abstract][Full Text] [Related]
3. How Thailand eliminated lymphatic filariasis as a public health problem.
Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
[TBL] [Abstract][Full Text] [Related]
4. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
[TBL] [Abstract][Full Text] [Related]
5. Assessment of microfilaremia in 'hotspots' of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance.
Mehta PK; Maharjan M
PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011932. PubMed ID: 38295107
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
Lupenza ET; Gasarasi DB; Minzi OM
PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration.
Jones C; Ngasala B; Derua YA; Tarimo D; Reimer L; Bockarie M; Malecela MN
Parasit Vectors; 2018 Nov; 11(1):588. PubMed ID: 30424781
[TBL] [Abstract][Full Text] [Related]
8. Low transmission of Wuchereria bancrofti in cross-border districts of Côte d'Ivoire: A great step towards lymphatic filariasis elimination in West Africa.
Yokoly FN; Zahouli JBZ; Méite A; Opoku M; Kouassi BL; de Souza DK; Bockarie M; Koudou BG
PLoS One; 2020; 15(4):e0231541. PubMed ID: 32282840
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
Kroidl I; Saathof E; Maganga L; Clowes P; Maboko L; Hoerauf A; Makunde WH; Haule A; Mviombo P; Pitter B; Mgeni N; Mabuye J; Kowuor D; Mwingira U; Malecela MN; Löscher T; Hoelscher M
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004618. PubMed ID: 27070786
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month longitudinal parasitological assessment of lymphatic filariasis-positive individuals: impact of a biannual treatment with ivermectin and albendazole.
Kanamitie JN; Ahorlu CS; Otchere J; Aboagye-Antwi F; Kwansa-Bentum B; Boakye DA; Biritwum NK; Wilson MD; de Souza DK
Trop Med Int Health; 2017 Nov; 22(11):1451-1456. PubMed ID: 28891597
[TBL] [Abstract][Full Text] [Related]
12. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
Nana-Djeunga HC; Tchouakui M; Njitchouang GR; Tchatchueng-Mbougua JB; Nwane P; Domche A; Bopda J; Mbickmen-Tchana S; Akame J; Tarini A; Epée E; Biholong BD; Zhang Y; Tougoue JJ; Kabore A; Njiokou F; Kamgno J
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005633. PubMed ID: 28662054
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
[TBL] [Abstract][Full Text] [Related]
14. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
McLure A; Graves PM; Lau C; Shaw C; Glass K
Epidemics; 2022 Sep; 40():100591. PubMed ID: 35816826
[TBL] [Abstract][Full Text] [Related]
15. Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia.
Endeshaw T; Taye A; Tadesse Z; Katabarwa MN; Shafi O; Seid T; Richards FO
Pathog Glob Health; 2015; 109(7):344-51. PubMed ID: 26878935
[TBL] [Abstract][Full Text] [Related]
16. Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007365. PubMed ID: 31009482
[TBL] [Abstract][Full Text] [Related]
17. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration.
Rao RU; Nagodavithana KC; Samarasekera SD; Wijegunawardana AD; Premakumara WD; Perera SN; Settinayake S; Miller JP; Weil GJ
PLoS Negl Trop Dis; 2014; 8(11):e3281. PubMed ID: 25393404
[TBL] [Abstract][Full Text] [Related]
19. Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.
Simonsen PE; Derua YA; Kisinza WN; Magesa SM; Malecela MN; Pedersen EM
BMC Infect Dis; 2013 Jul; 13():335. PubMed ID: 23870103
[TBL] [Abstract][Full Text] [Related]
20. Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
Ramaiah KD; Vanamail P; Yuvaraj J; Das PK
Trans R Soc Trop Med Hyg; 2011 Aug; 105(8):431-7. PubMed ID: 21601901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
